Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Abstract Text:

PURPOSE: AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell factor receptor. This phase I, dose-finding study evaluated the safety, pharmacokinetics, and pharmacodynamics of AMG 706 in patients with refractory advanced solid tumors. PATIENTS AND METHODS: AMG 706 was administered at escalating doses of 50 to 175 mg once daily or 25 mg bid for the first 21 days of a 28-day cycle. The 125-mg once-daily dose was also administered continuously. The maximum-tolerated dose (MTD), safety, pharmacokinetics, tumor response, and serum levels of proangiogenic markers were determined. RESULTS: Seventy-one patients received AMG 706. The MTD was 125 mg once daily administered continuously. The most frequent adverse events were fatigue (55%), diarrhea (51%), nausea (44%), and hypertension (42%). Plasma AMG 706 concentrations increased in a dose-proportional manner with no accumulation after multiple doses. Five patients (7%) had a partial response, 35 patients (49%) had stable disease (at least through day 50), and 31 patients (44%) had progressive disease. Changes in tumor size correlated significantly with an increase in placental growth factor (P = .003) and a decrease in soluble kinase domain receptor (P = .001). CONCLUSION: In this study of patients with advanced refractory solid tumors, AMG 706 was well tolerated and displayed favorable pharmacokinetics and evidence of antitumor activity. Additional studies of AMG 706 as monotherapy and in combination with various agents are ongoing.

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Publishing Authors By Initials

For similar peptides: intercellular signaling peptides and proteins: angiogenic proteins: vascular endothelial growth factors: vascular endothelial growth factor a research abstracts see: peptides: intercellular signaling peptides and proteins: angiogenic proteins: vascular endothelial growth factors: vascular endothelial growth factor a research

PUBMED ID PMID:

MEDLINE DATE:

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 2369-76

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 10

MONTH: Jun

YEAR: 2007

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Keywords Mesh Terms:

KEYWORDS: Vascular Endothelial Growth Factor A

MESH TERMS: drug effects

Chemical & Substance for Abstract: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Information

Substance Name: Niacinamide

Registry Number: 98-92-0

Grant and Affiliation Information for Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.

AFFILIATION: Premiere Oncology, Santa Monica, CA, USA.

Country: United States

AGENCY: United States NCI

GRANT: 5P30 CA016672-30

ACRONYM: CA

MEDLINETA: J Clin Oncol

REFSOURCE: J Clin Oncol. 2007 Jun 10;25(17):2340-2

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors Related Publications

• Bevacizumab/Chemotherapy in non-small-cell lung cancer: looking for a few good men?
• Dynamic studies of brain tumors by the use of digital fluoroscopy.
• Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
• Herellea corenal ulcer associated with the use of soft contact lenses.
• Metabolic management of advanced prostatic cancer.
• Methods of accurate localisation of non-palpable subdermal contraceptive implants.
• OP23.09: Ultrasonographic anatomy of perineum during pregnancy and immediately following obstetric injury.
• Observations in the effect of methoxy bisdehydro doisynolic acid as an estrogen.
• Perianal streptococcal dermatitis: an important differential diagnosis in pediatric patients.
• Relativity of chemical factors involved in cancer of the prostate and metabolic research.
• Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
• Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
• The mechanism of inflammation as applied in urology; practical aspects.
• [A plasmocytoma of the female urethra.]
• [A simple and inexpensive oxygen tent.]
• [ANOMALIES OF THE INFERIOR VENA CAVA.]
• [Clinical picture in patients with 46,X,i(Xq) karyotype. Are there differences from Turner syndrome?]
• [Diagnosis of posterior pneumomediastinum in newborn infants]
• [Duck plague in a water-bird flock]
• [EEG and vegetative dystonia.]
• [Familial progressive myoclonus epilepsy (Unverricht/Lundborg)]
• [INTUBATION ANESTHESIA FOR ABDOMINAL CESAREAN SECTION.]
• [In Process Citation]
• [New developments in the field of therapeutically useful organic sulfur compounds.]
• [New treatments for vitiligo?]
• [P4, a new substance for the treatment of Parkinson syndrome. Initial results of a clinical trial]
• [Patient-controlled analgesia with subcutaneous opoids for out-patients with severe tumour pain.]
• [Production and characteristics of bacteria-labeled talc dust for experimental air hygiene studies]
• [Research on the effect of 4-hydroxycoumarin derivative G 23350 on Shwartzman-Sanarelli phenomenon.]
• [The detection of antibodies against influenza A viruses (H1N1, H3N2) in swine with the single radial hemolysis (SRH) and the hemagglutination inhibition (HAH) tests]